Novartis AG is a global healthcare company that specializes in developing and manufacturing innovative pharmaceuticals and medical products. The company focuses on research-driven solutions in various therapeutic areas, including oncology, cardiology, immunology, and neuroscience, among others. Novartis is committed to improving patient health by providing high-quality medications and treatments, and it invests significantly in research and development to discover and deliver new therapies. In addition to its pharmaceutical division, Novartis also offers generics and biosimilars through its Sandoz division, making healthcare more accessible to patients worldwide. Read More
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential winners in this booming sector.
Novartis agreed to acquire Tourmaline Bio for $1.4 billion as pacibekitug shows strong trial results for inflammation and cardiovascular risk reduction.
Palantir is strengthening its role in the US industry through partnerships with Lear and Lumen and will showcase customer success stories at its AIPCon 8 event in September 2025.
The company stated that it has eliminated third-party manufacturing, specifically with Roush Industries, and has instead consolidated the B4 production line from Roush Industries to the company-owned plant in Tunica.
Shanghai, China, September 2, 2025 -- Amid a shifting global economy, the China International Import Expo (CIIE) continues to provide a vital gateway for global enterprises. With preparations for the 8th CIIE well underway, the expo is set to once again showcase innovation, foster cooperation, and expand access to the Chinese dynamic market.
Amid a shifting global economy, the China International Import Expo (CIIE) continues to provide a vital gateway for global enterprises. With preparations for the 8th CIIE well underway, the expo is set to once again showcase innovation, foster cooperation, and expand access to the Chinese dynamic market.
The global economic landscape remains deeply entrenched in a complex and often volatile trade conflict between the United States and China. What began in January 2018 as a series of targeted duties has escalated significantly through 2025, with both nations frequently adjusting and reinstating tariffs, creating a tangled web of
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy consumption of AI data centers is putting unprecedented strain on power grids and catalyzing a new wave of investment across traditional and
Novartis (NVS) offers a strong 3.55% dividend yield, backed by consistent payouts, solid profitability, and financial health—ideal for stable income investing.
